Leora Horn, MD, MSc, Ingram Associate Professor of Cancer Research; associate professor of medicine (Hematology and Oncology); assistant director of the Educator Development Program and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, discusses data from an updated analysis of the IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer (SCLC).
